|

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

RECRUITINGPhase 1Sponsored by Nuwacell Biotechnologies Co., Ltd.
Actively Recruiting
PhasePhase 1
SponsorNuwacell Biotechnologies Co., Ltd.
Started2025-06-06
Est. completion2026-07-01
Eligibility
Age40 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06978920

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.

Eligibility

Age: 40 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Ages between 40 and 75 years;
* Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;
* Disease history over 5 years;
* Stable dose of dopamine treatment;
* Able to undergo PET/CT/MRI detection;

Exclusion Criteria:

* Patients who have previously undergone brain surgery;
* Past use of stem cell therapy or participation in stem cell clinical research;
* Cognitive impairment;
* History of mental disorders;
* Patients with other serious systemic diseases;
* Past or current metastatic malignant tumors.

Conditions2

Parkinson DiseaseParkinson's Disease

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.